Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2021 | Targeting RET in lung cancer

Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, outlines therapeutic options for the treatment of patients with RET-positive lung cancer, highlighting the use of selpercatinib and pralsetinib in advanced disease. Dr Cappuzzo also discusses the importance of screening patients for RET rearrangements. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.